Home / Business and Economy / AtriCure Exec Sells $197K Stock Under Pre-Set Plan
AtriCure Exec Sells $197K Stock Under Pre-Set Plan
13 Sep
Summary
- CTO Salvatore Privitera sold 3,657 AtriCure shares on Sept. 8.
- The sale occurred under a pre-established Rule 10b5-1 trading plan.
- Privitera still holds nearly $7.9 million in AtriCure stock.
On September 8, 2026, Salvatore Privitera, Chief Technical Officer of AtriCure, sold 3,657 shares of company stock. The transaction, valued at approximately $197,000, was conducted under a Rule 10b5-1 trading plan established in February 2026. This indicates the sale's timing was predetermined well in advance.
Privitera's remaining equity in AtriCure remains substantial. He continues to hold a direct stake of approximately 147,000 shares, which had a market value of $7.9 million by the close of trading on September 8, 2026. The shares were sold at $55 each.
AtriCure, a medical device company specializing in cardiac tissue and nerve treatments, reported trailing twelve-month revenue of $569.6 million and a net income of $10.6 million. The company's stock has performed exceptionally well, increasing by 49% over the preceding 12 months, with shares closing at $53.73 on September 8, 2026.
